discuss
first
chapter
pharmaceut
industri
highli
research
base
littl
inhibit
research
chapter
look
futur
pharmaceut
research
move
differ
direct
includ
look
new
molecular
entiti
pharmaceut
biopharmaceut
regen
medicin
person
medicin
newer
better
drug
deliveri
long
aliv
suscept
diseas
may
elimin
diseas
newer
one
come
diseas
part
life
alway
search
new
medicin
treat
prevent
new
diseas
need
medicin
save
injur
peopl
accid
natur
disast
treat
older
peopl
whose
bodi
becom
suscept
ill
injuri
pharmaceut
industri
thu
integr
part
live
figur
carbon
chemic
symbol
c
silicon
chemic
symbol
si
belong
famili
chemistri
period
tabl
human
carbon
base
pharmaceut
industri
keep
carbon
factori
aliv
activ
chemistri
carbon
silicon
similar
somewhat
differ
figur
group
iv
pblock
period
tabl
properti
carbon
diversifi
silicon
carbon
nonmet
silicon
metalloid
silicon
comput
contain
manmad
virus
carbon
human
natur
virus
possibl
prevent
protect
carbonbas
human
natur
bacteria
virus
also
carbon
base
often
pathogen
life
threaten
averag
life
expect
around
world
twice
year
ago
world
becam
healthier
place
improv
public
health
sanit
clean
drink
water
number
vaccin
antibiot
medic
produc
mass
scale
distribut
grow
market
pharmaceut
industri
respons
medic
although
mani
medicin
cure
exist
natur
continu
discov
har
full
potenti
innov
technolog
industri
geneticist
chri
morri
institut
health
elderli
newcastl
england
estim
increas
life
expect
five
ten
year
next
year
result
improv
diet
medic
life
expect
develop
develop
region
around
world
shown
figur
pharmaceut
industri
develop
meet
need
new
medicin
treat
complic
diseas
newer
form
diseas
synthet
drug
develop
earli
twentieth
centuri
eg
acetylsalicyl
acid
aspirin
simpl
structur
nowaday
drug
complex
eg
atorvastatin
lipitor
recent
even
complex
synthet
biolog
eg
bevacizumab
avastin
introduc
market
figur
aspirin
use
year
tradit
nonsteroid
antiinflammatori
agent
recent
low
dose
blood
thinner
aspirin
help
maintain
blood
flow
reduc
platelet
aggreg
coagul
turn
help
prevent
heart
attack
recent
develop
atorvastatin
help
patient
heart
diseas
reduc
cholesterol
level
thu
target
root
caus
diseas
introduct
biopharmaceut
avastin
breakthrough
develop
treatment
avastin
monoclon
antibodi
specif
bind
target
protein
case
vascular
endotheli
growth
factora
vegfa
inhibit
activ
vegfa
necessari
factor
growth
blood
vessel
angiogenesi
cancer
tissu
need
develop
blood
vessel
surviv
grow
avastin
inhibit
angiogenesi
select
block
vegfa
therebi
help
control
cancer
journey
aspirin
avastin
show
signific
advanc
scienc
technolog
pharmaceut
industri
newer
diseas
old
diseas
newer
form
emerg
period
sever
acut
respiratori
syndrom
sar
multidrug
resist
tuberculosi
ebola
fever
hepat
c
pharmaceut
research
direct
develop
newer
better
drug
fight
howev
anticanc
drug
yet
exist
act
magic
bullet
case
penicillin
infecti
diseas
although
drug
use
treat
cancer
patient
case
live
extend
use
nonetheless
futur
develop
anticanc
drug
look
bright
one
monoclon
antibodi
avastin
antibodi
immunoglobulin
immun
protein
produc
antigen
introduc
bodi
monoclon
mean
produc
singl
clone
white
blood
cell
call
bcell
produc
antibodi
whenev
foreign
organ
bodi
bodi
immun
system
work
monoclon
antibodi
made
laboratori
specif
protein
also
use
alon
carri
certain
drug
radioact
particl
kill
cancer
cell
product
monoclon
antibodi
shown
figur
monoclon
antibodi
mab
drug
anticanc
drug
develop
market
biotechnolog
compani
one
innov
idea
use
make
cancer
cell
recogniz
foreign
bodi
immun
system
fight
cancer
cell
rituximab
brand
name
rituxan
specif
monoclon
antibodi
drug
attach
protein
receptor
found
bcell
caus
tumor
cell
disintegr
certain
mab
drug
block
growth
signal
cancer
cell
cetuximab
brand
name
erbitux
attach
receptor
cancer
cell
get
growth
signal
multipli
anoth
mab
drug
ibritumomab
brand
publish
woodhead
publish
limit
name
zevalin
tag
radioact
particl
give
radiat
cancer
cell
without
affect
normal
cell
idea
uniqu
reach
target
cancer
cell
commonli
known
target
therapi
us
fda
approv
number
monoclon
antibodi
drug
tabl
hundr
clinic
trial
pandem
appar
incur
diseas
affect
human
popul
pharmaceut
industri
abil
develop
medicin
fight
diseas
take
time
ultim
compani
abl
develop
medicin
extend
longev
cure
diseas
complet
acquir
immun
defici
syndrom
aid
exampl
diseas
began
caus
health
problem
death
peopl
scare
thought
world
end
pharmaceut
industri
develop
number
medicin
antiretrovir
drug
emtricitabin
tenofovir
ritonavir
atazanavir
efavirenz
azt
prolong
live
aid
patient
taken
combin
strategi
recogn
highli
activ
antiretrovir
therapi
haart
figur
expect
aid
vaccin
market
within
next
year
take
long
time
consider
staff
resourc
therefor
huge
money
develop
drug
accord
roch
drug
research
develop
resembl
big
number
game
figur
long
time
year
averag
take
develop
new
medicin
treat
particular
diseas
million
peopl
die
treatment
avail
happen
peopl
hivaid
aid
drug
began
market
million
peopl
die
around
world
peopl
nt
alway
respond
drug
way
one
drug
fit
everyon
recent
us
fda
announc
new
box
warn
anticlot
drug
clopidogrel
plavix
explain
less
effect
peopl
metabol
drug
convert
activ
form
drug
less
effect
peopl
variant
gene
liver
enzym
catalyz
clopidogrel
activ
form
situat
similar
peopl
lactos
intoler
lactas
enzym
defici
digest
cow
milk
gene
control
mani
thing
bodi
function
analysi
individu
genom
data
show
possibl
respons
particular
drug
futur
pharmaceut
industri
depend
provid
person
medicin
person
medicin
custom
tailormad
medicin
treatment
appropri
medicin
select
provid
optimum
therapeut
valu
individu
patient
accord
genom
makeup
figur
might
possibl
provid
right
treatment
right
person
right
time
near
futur
give
prescript
physician
need
determin
patient
singl
nucleotid
polymorph
snp
profil
compar
data
bank
figur
drug
work
best
patient
exampl
cancer
patient
physician
determin
right
dosag
specif
chemotherapeut
drug
without
use
trial
error
method
figur
trastuzumab
herceptin
kind
person
medicin
treatment
work
breast
cancer
patient
much
protein
tumor
genet
variant
enzym
respons
deactiv
cancer
drug
determin
level
enzym
dna
sampl
patient
analyz
base
snp
profil
similarli
cytochrom
enzym
respons
metabol
mani
drug
antidepress
anticoagul
proton
pump
inhibitor
peopl
metabol
drug
quickli
other
metabol
slowli
test
identifi
peopl
genet
publish
woodhead
publish
limit
variat
physician
make
correct
decis
prescrib
drug
dose
tailor
treatment
medicin
diagnost
advanc
afford
import
person
medicin
use
futur
gener
pharmaceut
medic
student
need
understand
genom
sequenc
data
dr
jeremi
berg
director
us
nation
institut
gener
medic
scienc
describ
combin
sourc
power
predict
diseas
person
like
develop
might
respond
certain
medicin
popul
longev
increas
healthcar
burden
older
peopl
burden
other
depend
activ
less
activ
usual
agerel
chronic
ill
alzheim
diseas
parkinson
diseas
dementia
arthriti
cancer
destruct
eye
diseas
type
ii
diabet
figur
doubt
demand
better
drug
area
continu
prioriti
object
advanc
drug
deliveri
technolog
improv
patient
complianc
produc
better
clinic
outcom
exampl
needleless
inject
mani
peopl
afraid
needl
prefer
needleless
inject
realiti
anoth
exampl
sustain
releas
tablet
one
time
simpl
tablet
avail
sustain
releas
tablet
half
releas
immedi
consumpt
half
releas
longer
period
near
futur
advanc
nanotechnologycontrol
releas
drug
especi
oral
administ
lipophil
drug
gener
watersolubl
bioavail
drug
limit
one
major
possibl
advanc
drug
develop
deliveri
futur
relat
gene
silenc
pathway
ribonucl
acid
interfer
rnai
technolog
known
messeng
rna
mrna
carri
instruct
dna
cell
nucleu
build
protein
diseas
link
either
mutat
abnorm
regul
gene
product
andrew
fire
craig
mello
discov
novel
phenomenon
short
doublestrand
rna
fool
cell
destroy
relev
mrna
translat
protein
discoveri
open
new
dimens
health
scienc
scientist
select
elimin
mutat
unwant
protein
root
caus
diseas
discoveri
fire
mello
nobel
prize
physiolog
medicin
pharmaceut
industri
immedi
consid
rnai
superior
therapeut
modal
small
moleculebas
convent
drug
discoveri
protocol
mani
gene
target
select
control
convent
small
molecul
drug
wherea
rnai
select
remov
diseasecaus
gene
system
rnai
activ
mainli
achiev
two
pathway
short
interf
rna
sirna
mirna
sirna
doubl
strand
select
shut
gene
cleav
relev
mrna
mirna
singl
strand
elimin
specif
mrna
inhibit
translat
sever
mrna
mani
rnai
product
clinic
trial
stage
market
near
futur
figur
illustr
rna
interfer
bodi
recent
mayo
research
use
rnai
method
mice
model
demonstr
possibl
silenc
gene
produc
alphasynuclein
believ
primari
caus
parkinson
diseas
publish
woodhead
publish
limit
boston
children
hospit
develop
complet
new
approach
drug
deliveri
system
research
use
tini
subcutan
implant
devic
contain
membranebas
nanogel
embed
magnetit
nanoparticl
releas
drug
turn
magnet
field
articl
nano
letter
research
show
drug
dose
deliv
directli
proport
durat
puls
main
object
drug
deliveri
system
deliv
intact
medic
specif
target
part
caus
littl
toxic
pharmaceut
research
tri
use
nanotechnolog
target
specif
drug
deliveri
use
differ
vehicl
biodegrad
polym
dendrim
electroact
polym
modifi
fulleren
pharmaceut
market
grow
everi
year
figur
accord
forecast
intercontinent
market
servic
im
world
market
steadili
grow
abl
expect
employ
opportun
industri
world
econom
crisi
may
lead
job
cut
figur
show
number
peopl
employ
us
bureau
labor
statist
report
pharmaceut
employe
usa
number
expect
increas
result
econom
crisi
start
earli
sever
industri
downsiz
pharmaceut
sector
downsiz
job
cut
sector
save
cost
healthcar
import
concern
develop
countri
develop
countri
though
cost
medicin
major
part
overal
healthcar
cost
develop
countri
signific
especi
chronic
depend
gener
drug
exact
copi
origin
brand
name
drug
activ
ingredi
strength
dosag
form
puriti
qualiti
stabil
safeti
efficaci
excipi
color
flavor
filler
may
result
econom
crisi
earli
growth
gener
market
drop
significantli
gener
market
stronger
futur
blockbust
drug
soon
offpat
patent
gener
compani
launch
gener
equival
europ
gener
market
grow
gener
make
almost
volum
sale
fraction
dollar
valu
nongener
drug
figur
british
gener
manufactur
associ
estim
price
gener
version
drug
often
undergo
reduct
origin
cost
brand
name
drug
within
week
two
factor
gain
gener
drug
immedi
access
market
reduc
cost
consum
guarante
drug
control
author
safeti
qualiti
efficaci
exampl
us
fda
medicin
healthcar
product
regulatori
agenc
mhra
uk
govern
bodi
respons
approv
gener
version
medicin
carri
extens
review
process
biolog
biotechnologybas
drug
gener
version
biotechnologybas
drug
known
biosimilar
followon
biolog
biolog
larg
complex
molecul
mixtur
molecul
debat
whether
would
difficult
make
gener
product
nongener
gener
product
equival
gener
version
biolog
unlik
small
molecul
drug
usual
protein
even
minor
variat
product
process
procedur
affect
final
conform
therebi
function
also
affect
efficaci
safeti
relev
biosimilar
biopharmaceut
product
includ
cytokin
hormon
clot
factor
vaccin
antibodi
market
around
world
patent
biolog
alreadi
expir
expir
introduct
gener
version
market
fast
approach
current
biotechnologybas
drug
especi
larg
molecul
monoclon
antibodi
expens
afford
mani
patient
price
reduc
regular
approv
process
carri
biosimilar
product
patent
expir
patent
amgen
blockbust
biolog
epoetin
alfa
brand
name
epogen
known
epo
expir
european
market
compani
us
patent
expir
gener
version
epo
avail
china
india
peru
brazil
amgen
sell
gener
epo
china
south
america
biosimilar
also
avail
gsk
engirix
b
hepat
b
vaccin
eli
lilli
humulin
human
insulin
develop
countri
big
market
futur
biosimilar
product
low
cost
biolog
figur
show
blockbust
biopharmaceut
high
market
potenti
biosimilar
product
tabl
list
differ
pharmaceut
biopharmaceut
mani
year
usa
european
countri
germani
uk
franc
itali
spain
japan
lead
global
pharmaceut
market
recent
countri
asia
latin
america
emerg
remark
market
growth
im
figur
show
china
brazil
russia
india
particular
emerg
new
market
pharmaceut
market
asia
africa
australia
grew
nearli
wherea
north
america
europ
grew
figur
china
india
popul
one
billion
peopl
countri
develop
econom
pharmerg
pharmaemerg
market
pois
signific
growth
accord
report
pricewaterhousecoop
india
join
top
ten
countri
market
valu
us
billion
modern
biotechnolog
widespread
applic
product
biopharmaceut
vaccin
diagnost
field
biopharmaceut
biotechnolog
applic
includ
drug
develop
genet
test
gene
therapi
pharmacogenom
human
insulin
first
biotechnolog
produc
medicin
develop
produc
genentech
market
eli
lilli
first
modern
biotechnolog
compani
genentech
acquir
roch
great
success
produc
number
biopharmaceut
product
everi
cell
bodi
origin
stem
stem
cell
receiv
instruct
bodi
stem
cell
start
divid
make
certain
gene
new
protein
process
differ
type
cell
nerv
blood
muscl
bone
skin
cell
produc
earli
life
growth
figur
cell
gene
control
intern
signal
extern
signal
come
chemic
hormon
secret
cell
two
type
natur
stem
cell
embryon
adult
stem
cell
embryon
stem
cell
extract
embryo
right
fertil
pluripot
mean
produc
type
fetal
adult
cell
anim
investig
contrast
adult
stem
cell
isol
matur
tissu
multipot
mean
produc
limit
type
cell
first
human
clinic
trial
use
stem
cell
began
octob
us
fda
approv
studi
biotech
medic
pharmaceut
research
believ
stem
cell
therapi
potenti
cure
chronic
diseas
current
stem
cell
therapi
includ
bone
marrow
transplant
treat
leukemia
cancer
leukemia
cancer
white
blood
cell
leukocyt
made
bone
marrow
cancer
leukocyt
grow
abnorm
fight
infect
treatment
includ
chemotherapi
andor
bone
marrow
transplant
healthi
bone
marrow
donor
given
patient
futur
research
expect
use
technolog
treat
differ
cancer
parkinson
diseas
spinal
cord
injuri
alzheim
diseas
multipl
sclerosi
muscl
damag
diabet
burn
osteoarthr
rheumatoid
arthriti
heart
diseas
current
stem
cell
transplant
method
one
major
drawback
howev
patient
bodi
reject
donor
stem
cell
even
though
screen
match
scientist
conduct
research
regener
new
tissu
laboratori
collect
healthi
adult
stem
cell
patient
transplant
cell
back
patient
regener
tissu
genet
ident
recipi
cell
graft
reject
occur
avail
isol
desir
adult
stem
cell
restrict
kind
regen
medicin
practic
restrict
mani
diseas
recent
discoveri
induc
pluripot
stem
cell
shown
light
overcom
limit
process
cell
fibroblast
reprogram
pluripot
stem
cell
use
differenti
desir
cell
type
treatment
patient
technolog
risk
free
howev
cell
may
divid
uncontrol
manner
gener
tumor
scientist
work
fine
tune
process
type
treatment
technolog
use
clinic
televis
news
program
show
robot
use
depth
ft
surfac
ocean
stop
gush
oil
spill
gulf
mexico
drug
discoveri
process
pharmaceut
industri
also
greatli
benefit
introduct
autom
robot
abil
identifi
new
drug
candid
million
compound
addit
use
advanc
bioinformat
help
scientist
creat
computeraid
design
new
drug
understand
molecular
pathway
diseas
threedimension
structur
protein
gener
practition
pleas
whenev
find
broad
spectrum
drug
one
wide
coverag
prescrib
base
symptom
without
clinic
diagnosi
patient
save
money
time
situat
howev
patient
treatment
use
broad
spectrum
drug
effect
free
side
effect
essenti
diseas
detect
earliest
stage
symptom
appear
extrem
accur
diagnosi
biomark
biochem
characterist
use
measur
diseas
treatment
stage
power
tool
could
use
futur
diagnos
treat
monitor
prevent
diseas
diagnost
test
current
use
identifi
diseas
need
offer
precis
assess
specif
person
treatment
earli
detect
diseas
understand
caus
may
help
physician
start
new
form
treatment
biomark
chronic
diseas
cancer
hiv
cardiovascular
diseas
alzheim
parkinson
develop
valid
drug
develop
specif
effect
particular
genet
trait
scienc
nanotechnolog
use
microscop
devic
atom
molecular
level
soon
go
revolution
diagnosi
treatment
diseas
gene
chip
technolog
alreadi
use
examin
analyz
genet
sequenc
quickli
identifi
activ
gene
diseas
tissu
futur
pharmaceut
r
work
forc
r
alway
primari
sector
develop
pharmaceut
industri
remain
medic
treatment
gradual
shift
tradit
toward
person
treatment
pharmacogenet
replac
convent
path
diagnos
diseas
evolut
newer
drug
develop
strategi
screen
method
toward
make
right
kind
biopharmaceut
futur
pharmaceut
r
work
forc
remain
multidisciplinari
inclin
toward
area
relat
molecular
genet
figur
